


Hamon Greater China Fund


26 February 2010

Unit Price
US\$10.74

Sector Weighting



Country Weighting



Fund Details

The investment objective of the Hamon Greater China Fund is to achieve capital appreciation by investing in the shares of the Greater China region, including China, Taiwan and Hong Kong

Launch date	10/3/2008
Authorisation	SFC and UCITS approved
Bloomberg Code	HAMGRCH ID
Dealing	Daily
Investment Advisor	Hamon Asset Mgmt. Ltd.

Important Information:

Investment involves risk. Past performance is not indicative to future performance. The fund may invest in emerging markets, smaller companies and derivative instruments and thus involve higher risk and volatility. Before investing, please refer to the offering document(s) for details, including the risk factors.

The document is issued by Hamon Investment Group and has not been reviewed by the SFC. It is not a recommendation, an offer or invitation to investment. Consult your financial advisor before making any investment decisions.

Fund in figures (NAV to NAV, with dividend reinvested)

Cumulative Performance % in US\$

(NAV in US\$)
Source: BNY Mellon, Bloomberg

	Feb 10	YTD	1 yr	Since Incept. (10 Mar 2008)
Hamon Greater China Fund	0.84%	-7.13%	123.67%	7.36%
MSCI AC Golden Dragon Net USD Index	0.70%	-6.91%	69.11%	-9.52%

Calendar Year Performance % in US\$

	2009	2008	2007	2006	2005
Hamon Greater China Fund	125.79%	-48.80%	-	-	-
MSCI AC Golden Dragon Net USD	66.66%	-41.68%	-	-	-

Highlights

- Inflation remains relatively tame in China.
- The NPC meetings in March will provide guidance for any upcoming policy changes in China.
- Earnings results generally positive to support markets.

Fund Review

The Hamon Greater China Fund rose 0.8% in February, largely in line with the MSCI Golden Dragon Index, which rose 0.7%. The market consolidation was due to industrial stocks, which were sold down as concerns over liquidity tightening prevailed and the correction in the Taiwanese market, due to fears of tech orders peaking out after Chinese New Year. Chinese financial stocks stabilised, supported by attractive valuations and with uncertainty of the rights issue becoming clearer.

Chinese equities we believe are attractively priced and the market has absorbed the negative news concerning the normalisation of China's liquidity. The H-Share index is currently trading on 12X 2010PE, with 25% EPS growth in 2010.

January's 1.5% CPI number was lower than market expectations and concerns over inflation remains relatively subdued. Investors will now closely monitor the upcoming National Committee of the Chinese People's Political Consultative Conference (CPPCC) and the National People's Congress (NPC) in March, which will set the political and economic tone for the year. The national meeting should institute further initiatives to refocus policies towards rural development and drive domestic consumption. The Fund has added some pharmaceutical related holdings, which may rally on the back of the country's healthcare reform.

In Taiwan, the Taix fell 3.1% during the month, as non-tech names performed better than tech due to the previous month's underperformance. Tech names saw selling pressure, as companies had margins squeezed by offering higher seasonal wages to offset labour shortages. Taiwan reported 4Q09 GDP growth of 9.2% YoY in January, due to stronger private consumption growth and better than expected trade figures. Total exports rose a surprising 75.8% YoY, while export orders were up 71.8%, driven by strong demand from Chinese companies looking to build inventory ahead of the Lunar New Year, while sales to the US continue to improve.

As concerns over inflation and monetary tightening begin to fade, we maintain a positive stance towards the market, including banks, property, building materials and commodity companies in the near term, while consumption, tech, "green" energy and healthcare sectors remain an area of focus for the medium term.